This is an open-label, non-comparative study aimed to evaluate the safety profiles and efficacy of patients with unresectable colorectal liver metastases treated by selective TACE (transarterial chemoembolization) using HepaSphere load with doxorubicin. Total of 15 patients will be planned to recruit.